Colon Cancer
805
114
165
355
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
95 trials with published results (12%)
Research Maturity
355 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.1%
65 terminated out of 805 trials
84.5%
-2.0% vs benchmark
7%
58 trials in Phase 3/4
27%
95 of 355 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 355 completed trials
Clinical Trials (805)
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Integrated Cancer Repository for Cancer Research
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Genomic Services Research Program
Risk Communication Within Mexican-American Families
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma
Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis
Collection of Blood From Patients With Cancer
A Study of PHN-012 in Patients With Advanced Solid Tumors
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NIMA-Colon Cancer Study
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer